{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Rotherham&max-questionFirstAnswered.=2018-11-23T13%3A51%3A55.143Z&max-answer.questionFirstAnswered.=2019-06-18T15%3A02%3A18.803Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberConstituency=Rotherham&max-questionFirstAnswered.=2018-11-23T13%3A51%3A55.143Z&max-answer.questionFirstAnswered.=2019-06-18T15%3A02%3A18.803Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Rotherham&_metadata=all&max-questionFirstAnswered.=2018-11-23T13%3A51%3A55.143Z&max-answer.questionFirstAnswered.=2019-06-18T15%3A02%3A18.803Z", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=Rotherham&max-questionFirstAnswered.=2018-11-23T13%3A51%3A55.143Z&max-answer.questionFirstAnswered.=2019-06-18T15%3A02%3A18.803Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Rotherham&max-questionFirstAnswered.=2018-11-23T13%3A51%3A55.143Z&max-answer.questionFirstAnswered.=2019-06-18T15%3A02%3A18.803Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Rotherham&max-questionFirstAnswered.=2018-11-23T13%3A51%3A55.143Z&max-answer.questionFirstAnswered.=2019-06-18T15%3A02%3A18.803Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1007772", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007772/answer", "answerText" : {"_value" : "
In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p>
<\/p>
An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "191930"} , {"_value" : "191931"} , {"_value" : "191932"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.303Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"} } , "tablingMemberConstituency" : {"_value" : "Rotherham"} , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"} ], "uin" : "191929"} , {"_about" : "http://data.parliament.uk/resources/1007773", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007773/answer", "answerText" : {"_value" : "
In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p>
<\/p>
An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "191929"} , {"_value" : "191931"} , {"_value" : "191932"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.35Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"} } , "tablingMemberConstituency" : {"_value" : "Rotherham"} , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"} ], "uin" : "191930"} , {"_about" : "http://data.parliament.uk/resources/1007775", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007775/answer", "answerText" : {"_value" : "
In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p>
<\/p>
An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "191929"} , {"_value" : "191930"} , {"_value" : "191932"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.407Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"} } , "tablingMemberConstituency" : {"_value" : "Rotherham"} , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"} ], "uin" : "191931"} , {"_about" : "http://data.parliament.uk/resources/1007776", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007776/answer", "answerText" : {"_value" : "
In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p>
<\/p>
An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "191929"} , {"_value" : "191930"} , {"_value" : "191931"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.453Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"} } , "tablingMemberConstituency" : {"_value" : "Rotherham"} , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"} ], "uin" : "191932"} , {"_about" : "http://data.parliament.uk/resources/1007778", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007778/answer", "answerText" : {"_value" : "
In July 2018, the Government Equalities Office published a report titled \u2018Improving LGBT lives: Government action since 2010\u2019 which is available at the following link:<\/p>
<\/p>